Janus Henderson Group PLC Raises Stock Position in DaVita Inc. $DVA

Janus Henderson Group PLC boosted its holdings in shares of DaVita Inc. (NYSE:DVA) by 96.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,188 shares of the company’s stock after buying an additional 18,237 shares during the quarter. Janus Henderson Group PLC owned 0.06% of DaVita worth $5,716,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Root Financial Partners LLC raised its holdings in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares in the last quarter. Caitlin John LLC acquired a new position in DaVita in the fourth quarter valued at $34,000. Canada Pension Plan Investment Board purchased a new position in DaVita during the 2nd quarter worth approximately $43,000. Sankala Group LLC purchased a new position in shares of DaVita during the fourth quarter worth approximately $39,000. Finally, iSAM Funds UK Ltd purchased a new position in DaVita during the 3rd quarter worth $46,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $181.10 on Friday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49. The business has a 50-day moving average of $218.65 and a two-hundred day moving average of $176.48. The stock has a market capitalization of $11.55 billion, a price-to-earnings ratio of 14.82, a price-to-earnings-growth ratio of 0.63 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same period in the prior year, the firm posted $2.95 EPS. The company’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts anticipate that DaVita Inc. will post 14.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DVA. UBS Group lifted their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Barclays raised their price objective on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $225.00.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported second-quarter adjusted earnings per share of $4.02, above the $3.88 analyst consensus, while revenue rose 5.2% year over year to $3.55 billion and free cash flow reached $256 million. DaVita Q2 2026 Earnings Call Highlights
• Positive Sentiment: Management highlighted clinical-led and mortality-related treatment-volume gains, broader access to middle-molecule drugs and strategic execution, while maintaining its 2026 adjusted EPS outlook of $14.10 to $15.20. DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
• Positive Sentiment: Barclays raised its price target from $218 to $224, although it retained an “equal weight” rating, signaling improved valuation potential but not a strong bullish conviction. Benzinga
• Positive Sentiment: Unusually high call-option activity—9,484 contracts versus typical volume of about 1,428—indicates increased speculative interest in a potential recovery, though it does not guarantee buying pressure in the stock.
• Neutral Sentiment: Value-focused analysis is monitoring DaVita’s earnings estimates, revisions, valuation and momentum trends. The stock’s relatively modest earnings multiple could attract value investors, but the near-term fundamentals remain mixed. Is DaVita a Great Value Stock Right Now?
• Negative Sentiment: Second-quarter margins narrowed and the company faced a weaker commercial-payer mix, while reimbursement pressure and policy transitions could constrain future profitability. Treatment volumes were characterized as broadly flat, making growth dependent on clinical trends and execution. DaVita Stock Down Despite Q2 Earnings Beat

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.90% of the stock is currently owned by corporate insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.